Short answer
MBX Biosciences, Inc. (MBX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$24M
- +1.5% YoY
- EPS (diluted)
- −$0.50
- +29.6% YoY
Source: XBRL data from the MBX Biosciences, Inc. (MBX) Q1 2026 10-Q on SEC EDGAR. USD.
MBX Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product sales, unchanged from prior year
- Net loss $23.5M vs $23.9M YoY; operating loss $27.3M vs $26.5M
- R&D expense $18.5M vs $22.4M; G&A expense $8.8M vs $4.1M
- Cash, equivalents and marketable securities $440.0M vs $262.1M at December 31, 2025
- Funding expected through 2029; Phase 3 canvuparatide trial planned for third quarter 2026
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Regulatory risk: Additional unknown risks could adversely affect operations or financial condition
- Operational risk: Risk events could materially harm business prospects and operating results
- Market risk: Adverse developments could reduce common-stock trading price
- Financial risk: Investors could lose all or part of their investment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MBX Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.